Browsing by Author "Pluhar, G. Elizabeth"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Immunotherapy yields breed-specific worst survival outcomes among three investigated therapies in French bulldogs with high-grade glioma, November 12, 2024
    (2024) Arnold, Susan; Taylor, Amanda; Hansen, Katherine; Low, Walter; Pluhar, G. Elizabeth
    French bulldogs are one of the most popular dog breeds in the United States and are also among breeds with the highest risk for developing high-grade glioma (HGG). With limited treatment options and high translational value for studying canine HGG to advance understanding of human glioblastoma (GB), a variety of novel treatment options have been investigated. In other forms of cancer, immunotherapy has shown promising results, garnering interest in the treatment of HGG. Yet, when an immunotherapy-based clinical trial was conducted, a marked survival disparity in French bulldog patients compared to other breeds was observed. This retrospective, multi-institutional study was conducted to examine survival outcomes in immunotherapy-treated French bulldogs compared to closely related breeds, and to French bulldogs treated with several other treatment modalities. French bulldogs treated with immunotherapy experienced significantly shorter overall survival (OS) than Boxers and Boston terriers (132 vs. 221 days, respectively). French bulldogs treated with immunotherapy had no significant difference in OS compared to French bulldogs treated palliatively, whereas dogs treated with either a novel therapy involving sonodynamic therapy or stereotactic radiation therapy had significantly longer OS. This study provides evidence for a French bulldog-specific, immunotherapy-resistant form of HGG, suggesting that the breed harbors key molecular differences affecting the tumor and tumor-immune microenvironment and subsequent poor response to treatment.
  • Thumbnail Image
    Item
    Survival data from glioma-bearing French bulldogs treated with immunotherapy, stereotactic radiation therapy, sonodynamic therapy, and palliative care
    (2024-11-21) Arnold, Susan; Taylor, Amanda; Hansen, Katherine; Agarwal, Vijay; Low, Walter; Pluhar, G. Elizabeth; saarnold@umn.edu; Arnold, Susan; University of Minnesota Canine Brain Tumor Program
    This retrospective, multi-institutional study was conducted to examine survival outcomes in immunotherapy-treated French bulldogs compared to closely related breeds, and to French bulldogs treated with several other treatment modalities. French bulldogs treated with immunotherapy experienced significantly shorter overall survival (OS) than boxers and Boston terriers (132 vs. 221 days, respectively). French bulldogs treated with immunotherapy had no significant difference in OS compared to French bulldogs treated palliatively, whereas dogs treated with either a novel therapy involving sonodynamic therapy or stereotactic radiation therapy had significantly longer OS. This study provides evidence for an immunotherapy-resistant form of HGG in French bulldogs, suggesting that the breed harbors key molecular differences affecting the tumor and tumor-immune microenvironment and subsequent poor response to treatment.
  • Thumbnail Image
    Item
    Transcriptomic data from RNA Sequencing of canine high grade glioma tumor samples
    (2024-11-15) Arnold, Susan A; Pluhar, G. Elizabeth; Abrahante Llorens, Juan E; saarnold@umn.edu; Arnold, Susan; University of Minnesota Canine Brain Tumor Program
    These files contain the raw data for bulk RNA sequencing performed on canine high grade glioma tumor samples. These samples were obtained from three breeds of dogs: French bulldogs, boxers, and Boston terriers. All dogs were enrolled in immunotherapy clinical trials within the University of Minnesota Canine Brain Tumor Program. They were obtained from two different time points relative to treatment: pre-treatment and post-treatment. Treatment consisted of surgical resection and immunotherapy. The purpose of these data are to provide a comprehensive profile of how canine high grade glioma transcriptomes change in response to immunotherapy treatment, and to determine if there are breed-associated changes in differential gene expression.